摘要
目的探讨在颈动脉粥样硬化患者中，载脂蛋白AI（apolipoproteinAI，apoAI）、载脂蛋白B100（apolipoproteinB1‰apoB100）及apoB100／apoAI与急性冠脉综合征（acutecoronary syndrome，ACS）的相关关系。方法选取80例颈动脉粥样硬化患者，40例确诊为ACS（ACS组），40例己排除冠心病（对照组），检测患者的apoAI、apoBl0n、apoBl00／apoAI。结果ACS组患者apoAI显著低于对照组（P=0．001），apoB100（P=0．040）、apoBlodapoAI（P=0．005）则显著升高，多因素Logistic回归提示apoAI是颈动脉粥样硬化患者发生ACS的保护因素（95％CI：0．51～O．83），而apoBlodapoAI（95％CI：1．14～1．48）则是危险因素。结论在颈动脉粥样硬化患者中，apoAI、apoB100/apoAI可能会影响ACS的发生，临床应积极检测，必要时予以药物干预调整。
Objective To explore the relavance between biomarkers [apolipoprotein A I （apo A I ）, apolipoprotein B10o（apo B10o） and apo B100/apo AI ] and acute coronary syndrome（ACS） in carotid atherosclerosis patients. Method Eighty atheroselerosis patients were collected in this study, including 40 patients diagnosed as ACS in the ASC group and the other 40 patients in the control group.To detect apoA I, apoB100 and apo B100/apo A I of the two groups. Result The level ofapo A I in the ACS group is significantly lower than the control group（P=0.001）. Meanwhile, the levels of apoB100（P=0.040） and apo Bl00/apo A I （P=0.005） in the ACS group significantly increase. Multiple logistic regression analysis shows that apo A I is a protective factor（95%CI： 0.51~0.83） but apo B100/apo A I （95%CI： 1.14~1.48） play as a risk factor. Conclusion In carotid atherosclerosis patients, apoA I and apoB100/apoA I may affect the occurrence of ACS.The detection of apoA I and apoB100/apoA I are encouraged in clinic, which is supposed to instruct the drugs treatment.
出处
《中国医刊》
CAS
2016年第1期53-56,共4页
Chinese Journal of Medicine
基金
国家自然科学基金(81460223)
